Baseline quality of life predicts survival in patients with advanced colorectal cancer (Q43417492)

23 November 2017

Baseline quality of life predicts survival in patients with advanced colorectal cancer (English)

1 reference

23 November 2017

1 reference

1 reference

6

1 reference

23 November 2017

Maisey NR

1

1 reference

23 November 2017

Norman A

2

1 reference

23 November 2017

Watson M

3

1 reference

23 November 2017

Allen MJ

4

1 reference

23 November 2017

Hill ME

5

1 reference

23 November 2017

1 July 2002

1 reference

European Journal of Cancer

23 November 2017

1 reference

23 November 2017

38

1 reference

23 November 2017

10

1 reference

23 November 2017

1351-1357

1 reference

Compliance in quality of life data: a Norwegian experience

23 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Ensuring the quality of quality of life data: the Southwest Oncology Group experience

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. The importance of patients' subjective experience of disease and psychosocial well-being

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Quality of life assessment. An independent prognostic variable for survival in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Influence of psychological response on survival in breast cancer: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Effect of psychosocial treatment on survival of patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Effects of psychosocial treatment in prolonging cancer survival may be mediated by neuroimmune pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Nutrition support in patients with cancer: what do the data really show?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

Total parenteral nutrition and cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900098-9

7 January 2021

10.1016/S0959-8049(02)00098-9

Identifiers

DOI

1 reference

23 November 2017

1 reference